Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 17:00 save search
Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical PsychiatryAXS-05
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
AXSM | $68.26 -1.29% -1.3% 430K
|
Health Technology
|
| O: 10.36%
H: 0.0%
C: 0.0%
axs-05 trial therapeutics publication phase 3 major depressive disorder
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46%
|
Health Technology
|
| O: 1.71%
H: 1.69%
C: -0.56%
conference trial therapeutics phase 3
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
ESPR | $1.93 -16.45% -19.69% 6.8M
|
Health Technology
|
| O: -0.72%
H: 8.5%
C: 8.14%
phase 3
Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
VAXX | $0.4434 -8.99% -9.88% 450K
|
|
| O: 1.0%
H: 1.31%
C: -1.73%
covid-19 vaccine phase 3
Equillium Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease
Published: 2022-03-04 (Crawled : 17:00) - biospace.com/
EQ | $1.75 -5.41% -5.71% 86K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
disease phase 3
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
SKYE | $9.17 -20.98% 27K
|
Transportation and Warehousing
|
| O: 0.0%
H: 7.42%
C: 0.26%
glaucoma drug trial phase 1 bioscience phase 2 phase 3
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
Published: 2022-02-22 (Crawled : 17:00) - globenewswire.com
BTAI 4 | $2.73 -5.86% -6.23% 480K
|
Health Technology
|
| O: -1.78%
H: 1.69%
C: -4.06%
bxcl501 america order trial therapeutics cel phase 3
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February
Published: 2022-02-04 (Crawled : 17:00) - prnewswire.com
BMRN S | $91.51 -0.77% -0.78% 1.9M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
europe order gene therapy presentation therapy phase 3 haemophilia
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Published: 2022-01-25 (Crawled : 17:00) - biospace.com/
ANVS | $11.19 -3.78% -0.89% 150K
|
Health Technology
|
| O: 2.75%
H: 5.63%
C: -1.27%
fda parkinson disease positive phase 3 buntanetap
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.3073 -20.27% -8.85% 0
|
Health Technology
|
| O: 1.03%
H: 2.75%
C: -2.6%
sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
IOBT | $1.51 -2.58% -2.65% 130K
|
|
| O: -2.3%
H: 0.95%
C: 0.0%
trial trial results phase 1 results biotech iot phase 2 phase 3
Alpine 4 Holdings (ALPP) Subsidiary, Vayu Aerospace Corporation, Advances to Phase 3 of our US Air Force SBIR Allowing for Sole Source Procurement
Published: 2021-11-17 (Crawled : 17:00) - prnewswire.com
ALPP | $0.741 -4.39% -4.59% 79K
|
Manufacturing
|
| O: -5.6%
H: 24.11%
C: 15.02%
space spac phase 3
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
Published: 2021-11-15 (Crawled : 17:00) - biospace.com/
PHAS | $0.0701 -23.97%
|
Health Technology
|
| O: 1.35%
H: 8.8%
C: -19.47%
bleeding results phase 3 trial bentracimab
Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021
Published: 2021-11-12 (Crawled : 17:00) - biospace.com/
MDGL M | $231.33 -2.22% -2.27% 320K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
disease liver disease positive phase 3 liver
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
Published: 2021-11-10 (Crawled : 17:00) - biospace.com/
URGN | $15.105 0.03% 0.03% 660K
|
Health Technology
|
| O: 0.27%
H: 3.21%
C: -1.07%
phase 3 pharma
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Published: 2021-11-04 (Crawled : 17:00) - eyenoviabio.com
EYEN | $0.5473 -7.55% -8.17% 1.7M
|
Health Technology
|
| O: 5.78%
H: 0.0%
C: -3.8%
eye phase 3 trial enroll 8 billion market presbyopia
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Published: 2021-10-26 (Crawled : 17:00) - biospace.com/
KRYS | $169.695 -2.26% -2.31% 280K
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: 0.0%
treatment biotech phase 3 iot
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
Published: 2021-10-26 (Crawled : 17:00) - biospace.com/
ALKS | $24.0 -1.72% -1.75% 2.7M
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: 0.0%
cancer nemvaleukin phase 3 ovarian cancer trial
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
PSTX | $2.43 -10.99% -12.35% 600K
|
Health Technology
|
| O: 1.4%
H: 0.28%
C: -20.44%
phase 1 car-t results trial phase 2 phase 3
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderONWARD trial enrollment closed; trial completion expected in Q1 2022
Published: 2021-08-31 (Crawled : 17:00) - biospace.com/
ADIL | $2.61 12.02% 10.73% 3.3M
|
Health Technology
|
| O: 2.54%
H: 3.19%
C: -3.19%
alcohol use disorder treatment phase 3 trial enroll
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.